Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS) announced earnings for full year that Dropped, from last year
The company's bottom line came in at RMB937.931 million, or RMB2.91 per share. This compares with RMB1.051 billion, or RMB3.26 per share, last year.
The company's revenue for the period rose 6.2% to RMB2.981 billion from RMB2.806 billion last year.
Tibet Rhodiola Pharmaceutical Holding Co. earnings at a glance (GAAP) :
-Earnings: RMB937.931 Mln. vs. RMB1.051 Bln. last year.-EPS: RMB2.91 vs. RMB3.26 last year.-Revenue: RMB2.981 Bln vs. RMB2.806 Bln last year.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.